Stay updated with breaking news from Solution Group Bhd. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The inhalable version of CanSino’s Recombinant Covid-19 Vaccine (Adenovirus Type 5 Vector) has received clinical trial approval in Malaysia, says Solution Group Bhd (SGB).
IT WAS reported that the Health Ministry has approved CanSino’s single-dose Convidecia vaccine to be used as a heterologous booster with all Covid-19 primary vaccines in Malaysia. Is this true?
KUALA LUMPUR: The Health Ministry has approved CanSino’s single-dose Convidecia vaccine to be used as a heterologous booster with all Covid-19 primary vaccines in Malaysia.
KUALA LUMPUR, March 21 — The Ministry of Health (MOH) has approved CanSino’s single-dose Convidecia Covid-19 vaccine to be used as a heterologous booster. The MOH, in a statement on its website today, said application for the CanSino-type booster dose would be available via MySejahtera soon. It...
Based on corporate announcements and news flow on Friday, companies in focus on Monday (Feb 21) may include: Axiata Group Bhd, Digi.com Bhd, Maxis Bhd, Hock Seng Lee Bhd, Solution Group Bhd, Jerasia Capital Bhd, Sime Darby Plantation Bhd, Inari Amerton Bhd, KPJ Healthcare Bhd, Malaysia Smelting Corp Bhd and Petra Energy Bhd. Four mobile network operators (MNOs) — Celcom Axiata Bhd, Digi Telecommunications Sdn Bhd, Maxis Bhd and U Mobile Sdn Bhd — have recommended that the government allow a dual wholesale network (DWN) model which will be developed and operated by two consortiums involving...